Prostate-Specific Antigen (PSA) in Women: What It Means

Women produce prostate-specific antigen, and the name is misleading enough to cause real confusion. PSA shows up in female blood, breast milk, amniotic fluid, and several tissues, though at concentrations far below what is typical in men. The median PSA level in healthy women is roughly 0.002 ng/mL, compared with the 0.5 to 4.0 ng/mL range considered normal in adult men. That enormous gap once led researchers to dismiss female PSA as background noise, but decades of work have shown it is biologically meaningful, with relevance to conditions ranging from polycystic ovary syndrome to breast cancer prognosis.

The Female Prostate Is a Real Organ

The primary source of PSA in women is the same type of tissue that produces it in men: prostatic glandular tissue. In women, these are the Skene’s glands, a pair of small structures flanking the urethral opening. The name “Skene’s glands” persisted in anatomy textbooks for over a century, but researchers have increasingly argued that the tissue deserves to be called the female prostate, because it shares structural, functional, and immunohistochemical features with the male prostate. Skene’s gland tissue expresses PSA in the same specialized secretory cells that produce it in men, and it can develop similar pathologies, including hyperplasia and, rarely, adenocarcinoma.¹

A recent case report illustrated just how closely female prostatic tissue can mirror its male counterpart. A woman was found to have massive adenomyomatous hyperplasia of the Skene’s gland in the bladder neck area, and tissue staining was strongly positive for both PSA and a prostate-specific transcription factor called NKX3.1, confirming the diagnosis as female prostate tissue.² These cases are uncommon enough to get published individually, but they reinforce the point: women have prostatic tissue, and it behaves like prostatic tissue.

PSA Shows Up in Many Tissues Beyond the Prostate

The Skene’s glands are not the only source of PSA in women. The protein or its genetic instructions have been detected in a surprisingly wide array of tissues. Researchers using immunological and molecular methods have found PSA protein or its messenger RNA in roughly 30 to 40 percent of breast tumors, and at lower rates in tumors of the lung, colon, ovary, liver, kidney, and adrenal glands.³ PSA has also been identified in normal breast tissue, skin tumors, salivary gland tumors, and normal endometrium.

The salivary gland finding is particularly striking because it places PSA production in a tissue with no obvious connection to reproduction. Immunohistochemistry in both the parotid and submandibular glands has revealed PSA expression in the serous secretory cells and in the ducts, with the protein visible in tiny cytoplasmic vesicles and sometimes released into the glandular lumen.⁴ This means the enzyme once assumed to be exclusive to the prostate is distributed across tissues in both sexes. In women, these non-prostatic sources likely contribute the trace amounts of PSA detectable in the bloodstream.

How Much PSA Is Normal in Women

A study of over a thousand women measured serum PSA and found the highest concentration among them was 0.9 ng/mL, with a median around 0.002 ng/mL. Women with hyperandrogenic syndromes had levels that could climb to about 0.6 ng/mL, still well below the standard male range.⁵ Most routine clinical PSA assays were designed for men and have detection limits that sit right around or above typical female PSA levels, which is why standard bloodwork often reports a woman’s PSA as undetectable.

Ultrasensitive assays can pick up these low concentrations, but they bump into a different problem. When researchers tested six ultrasensitive PSA assays using blood from healthy women and from men who had had their prostates surgically removed, they found measurable PSA in both groups, sometimes up to 0.69 ng/mL in women. The biologic floor of the assays was up to 30 times higher than the stated analytic detection limit, meaning the test’s real-world sensitivity for tracking tiny changes is worse than its specifications suggest.⁶ This has made it tricky to use PSA as a precise biomarker in women, though experimental sensor technologies have brought detection down to the picogram range needed to distinguish normal from abnormal female levels.⁷

Hormones That Control PSA Production in Women

In men, testosterone is the main driver of PSA production. In women, the picture is more complicated and more interesting. Work on breast cancer cell lines has shown that PSA gene expression in female tissues responds to androgens, progestins, and glucocorticoids, but not to estrogens. Critically, the progesterone receptor and the androgen receptor can each independently switch on the PSA gene. A progestin that does not bind the androgen receptor still ramps up PSA production, and a drug that blocks the androgen receptor but has progestational activity does the same thing. An antiprogestin, on the other hand, can completely shut down the progesterone-driven signal.⁸

This dual hormonal control matters for understanding why PSA levels fluctuate in women. A woman’s androgen and progesterone levels shift across the menstrual cycle, during pregnancy, and in conditions like polycystic ovary syndrome. Each of those hormonal shifts can nudge PSA production up or down independently. It also explains why PSA tends to appear in hormone-receptor-positive breast tumors more than in hormone-receptor-negative ones: the hormonal machinery needed to turn on the PSA gene overlaps with the machinery that drives certain breast cancers.

PSA and Polycystic Ovary Syndrome

Because androgens stimulate PSA production, women with excess androgens tend to have higher serum PSA levels. The clearest example is PCOS, a condition affecting roughly one in ten women of reproductive age, characterized by elevated androgens, irregular ovulation, and often insulin resistance. A meta-analysis pooling data from multiple studies found that women with PCOS had significantly higher PSA levels than healthy controls.⁹ A separate systematic review and meta-analysis confirmed the same direction, reporting that mean PSA levels were substantially elevated in PCOS women compared with healthy peers.¹⁰

Individual studies have dug into which specific androgens correlate with PSA. In one, PSA levels tracked positively with total testosterone, DHEAS (an androgen precursor made by the adrenal glands), and clinical hirsutism scores. PSA also correlated negatively with SHBG, a protein that binds androgens and reduces their biological availability, meaning that when more “free” androgen was circulating, PSA went up.¹¹ Whether PSA could eventually serve as a practical clinical marker for androgen excess remains an open question. It reflects androgen activity at the tissue level rather than just what is floating in the blood, which could in theory make it a useful complement to standard hormone panels. But the assay challenges described earlier, where typical lab equipment cannot reliably measure such small concentrations, have kept PSA from entering routine PCOS workups.

What PSA in Breast Tissue Tells Us

One of the most studied roles for PSA in women involves breast cancer prognosis. PSA protein has been found in normal breast tissue, benign breast conditions, and breast tumors, but the pattern of expression across those categories is not what you might expect. In a study of 199 breast tumors, 48 benign breast disease specimens, and 36 normal breast tissue samples, significant PSA concentrations were found in about 28 percent of the tumors, 65 percent of benign breast disease samples, and 33 percent of normal breast tissues.¹² In other words, benign breast conditions were the most likely to express PSA, and advanced-stage cancers were the least likely.

That pattern turned out to be clinically meaningful. When researchers tracked outcomes in breast cancer patients, those whose tumors were PSA-positive had lower risks of relapse and death. The association held up even after accounting for other prognostic factors like tumor size and lymph node involvement, making PSA an independent favorable prognostic marker. PSA-positive tumors were more likely to be estrogen-receptor positive, to be caught at an early stage, and to be smaller.¹³ Additional clinical work has confirmed the link: women whose breast cancers expressed PSA had better disease-free survival and better overall survival than women with PSA-negative tumors.¹⁴

The reason this favorable relationship exists probably circles back to hormones. PSA expression tracks with hormone-receptor positivity, and hormone-receptor-positive breast cancers tend to be less aggressive and more responsive to hormonal therapy. PSA may also have a direct biological role: it is a protease, an enzyme that breaks down certain proteins, and some researchers have speculated that it could degrade growth factors involved in tumor progression. That idea is not settled, but the prognostic value of PSA in breast tumors has been replicated enough that it is considered a legitimate, if not yet routine, biomarker.

A Clue in Blood PSA Forms

There is an intriguing twist involving the molecular forms of PSA circulating in the blood of women with breast cancer. PSA exists in two main states: “free” PSA, which floats unattached, and “complexed” PSA, which is bound to other proteins. In men, the ratio of free to total PSA is used to help distinguish prostate cancer from benign prostate enlargement. In women, the ratio may carry a different signal. One study found that among breast cancer patients, about 84 percent had free PSA as the predominant form in their serum, compared with none of the healthy controls and almost none of the women sampled after surgery.¹⁵ This dramatic shift suggests that the form of PSA, not just the total amount, could be useful for detecting breast malignancies.

A separate investigation tested whether total and free PSA levels could distinguish benign from malignant breast masses. It reported that both total and free PSA were higher in women with malignant tumors, and found cut-off values that performed remarkably well in separating the two groups.¹⁶ These results are preliminary and come from individual studies, not large-scale clinical validation. But they point toward a future where a blood test already mass-produced for male prostate screening could be adapted to help evaluate breast lesions in women.

PSA in Breast Milk and Amniotic Fluid

PSA is not confined to blood and tissue. It has been measured in breast milk of lactating women, with concentrations ranging enormously from undetectable up to 350 micrograms per liter. The median was about 0.47 micrograms per liter, orders of magnitude higher than what circulates in the blood.¹⁷ Why PSA appears in breast milk at all is not entirely clear. As a serine protease, it might play a role in modifying milk proteins for the infant’s digestion, but that remains speculative.

PSA also appears in amniotic fluid. Studies examining amniotic fluid samples across pregnancy found PSA in nearly all specimens tested. Its concentration rises from around gestational week 11 to about week 21 or 22, then either stabilizes or decreases toward delivery.¹⁸¹⁹ The source of this amniotic PSA likely includes the fetal prostate (in male fetuses), but the presence of PSA in amniotic fluid from female pregnancies confirms maternal or fetal non-prostatic sources as well. The biological purpose, if any, remains unknown.

Skene’s Gland Tumors and PSA as a Tracking Marker

Adenocarcinoma of the Skene’s glands is extremely rare, but when it occurs, it can produce measurable serum PSA elevations, sometimes reaching levels normally seen only in men. In one reported case, the patient’s serum PSA was elevated before surgery and dropped promptly after the tumor was removed, mirroring the pattern clinicians rely on for tracking prostate cancer in men. The authors recommended that serum PSA be used for pre- and postoperative monitoring in patients with adenocarcinomas of the female urethra or periurethral glands.²⁰

Pathologists working on these rare tumors use PSA staining along with other markers to confirm that the tissue originates from the female prostate. Results are not always uniform. In a study of ectopic prostatic tissue and related cervical lesions, PSA staining was positive in some Skene’s gland derivatives but not in all, while a related marker (prostatic-specific acid phosphatase) was more consistently positive across specimen types.²¹ This means pathologists cannot rely on PSA staining alone when identifying female prostatic tissue, especially in unusual locations.

Why This Matters for Forensic Testing

PSA testing has a role outside clinical medicine that makes the female PSA question unexpectedly important: forensic investigations of sexual assault. Rapid semen-screening kits detect PSA on vaginal swabs as evidence of seminal fluid. Because PSA is present at high concentrations in semen, a positive result on a swab is typically interpreted as evidence of sexual contact. The problem is that women produce their own PSA, and certain medical conditions can raise it. If a forensic examiner does not account for this, a false positive is possible.

A forensic case report highlighted precisely this issue, noting that PSA can be detected in women’s bodies under various pathological conditions and stressing that proper interpretation of PSA-based tests requires knowing the victim’s medical history and the full circumstances of the case.²² A woman with a Skene’s gland condition, hyperandrogenism, or even recent breastfeeding could theoretically produce enough local PSA to trigger a positive semen-screening result. This does not mean the kits are unreliable in most circumstances, since the PSA concentration in semen dwarfs anything a woman’s tissues typically produce. But in edge cases, especially when time since alleged assault is long or sample quantity is small, the distinction matters, and confirmatory testing beyond PSA alone is warranted.

The Variability of the Female Prostate Itself

One reason female PSA research has moved slowly is that the Skene’s glands are not anatomically consistent across women. Unlike the male prostate, which is a well-defined organ surrounding the urethra, the female prostate varies dramatically in size and sometimes appears to be functionally absent. Autopsy and histological studies have found that some women have well-developed Skene’s glands with abundant glandular tissue, while others have rudimentary or barely detectable structures. This means the baseline capacity to produce PSA differs from woman to woman in a way that has no real parallel in men.

That variability complicates any effort to establish universal reference ranges for female PSA. A woman with well-developed Skene’s glands and moderate androgen levels might register a serum PSA of 0.05 ng/mL on an ultrasensitive assay, while a woman with rudimentary glands and similar hormone levels might be undetectable. Both are normal. Until the anatomy is better characterized across large populations, and until assays sensitive enough to reliably measure female-range PSA become standard, clinical reference ranges for women will remain a work in progress. For now, PSA measurement in women is largely a research tool and a diagnostic aid in specific rare conditions, not a screening test with established guidelines.